Abstract
In total, 97 acute ST-segment elevation myocardial infarction (STEMI) patients who received an emergency percutaneous coronary intervention (PCI) were enrolled and divided into a ticagrelor group and a clopidogrel group. Thrombolysis in myocardial infarction (TIMI) blood flow and the corrected TIMI frame count (CTFC) were used to assess the blood perfusion of culprit vessels. Thromboelastography (TEG) was used to evaluate the antiplatelet effect of drugs. The results showed that the incidence of TIMI grade III blood flow in the ticagrelor group was significantly higher than that in the clopidogrel group. The CTFC in the anterior descending, circumflex, and right coronary arteries was statistically significantly lower in the ticagrelor group as compared with that in the clopidogrel group. At 2 h and 7 d postdrug treatment, the adenosine diphosphate-induced platelet inhibition rate (ADP%) in the ticagrelor group increased significantly as compared with that in the clopidogrel group, and the platelet aggregation rate of the ADP pathway (MAADP) decreased significantly in the ticagrelor group versus that in the clopidogrel group. In conclusion, ticagrelor significantly improved TIMI blood flow and had a better antiplatelet effect than clopidogrel in STEMI patients undergoing an emergency PCI.
Highlights
With improvements in people’s living standards and changes in diets and lifestyles, there have been marked changes in the disease spectrum, with cardiovascular diseases a leading cause of death and disability.About 20 million people worldwide die each year of cardiovascular diseases [1,2,3]
The primary treatment for patients with an acute segment elevation myocardial infarction (STEMI) is the early opening of the infarct-related blood vessels, which restores reperfusion of blood flow in the infarcted area, reduces the infarct size, prevents ventricular remodeling, and eventually improves the patient’s shortterm and long-term prognosis [16]
Our study showed that the incidence of Thrombolysis in myocardial infarction (TIMI) grade III blood flow in the ticagrelor group was significantly higher than that in the clopidogrel group, which was inconsistent with the findings of the PLATO study where the incidence of TIMI grade III blood flow was similar in the ticagrelorand clopidogrel-treated groups [19]
Summary
With improvements in people’s living standards and changes in diets and lifestyles, there have been marked changes in the disease spectrum, with cardiovascular diseases a leading cause of death and disability. About 20 million people worldwide die each year of cardiovascular diseases [1,2,3]. In China, the toll of cardiovascular-related illnesses is severe, with an estimated 290 million cardiovascular patients, accounting for 44.8% and 41.9% of total deaths in rural and urban areas, respectively. An ST-segment elevation www.aging-us.com myocardial infarction (STEMI) shows a rapid onset. Among cardiovascular diseases, it is associated with the highest mortality [4]. According to a previous study, STEMI-related mortality during hospitalization of patients in China was 5.6%, and 30d mortality of males and females was 8.2% and 17.3%, respectively. STEMIs place a great burden on patients and society [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
